ICFG UK helped Biotherapy Services to raise funding from Foresight Group
| Seller | Biotherapy Services Ltd |
| Target | Biotherapy Services Ltd |
| Deal Type | Debt & Equity Financing |
| Buyer | Foresight Group |
| Territory | UK |
| Transaction Description | BTS is a clinical stage, Biopharmaceutical company developing and delivering novel autologous regenerative therapies, currently in clinical development for complex and chronic wounds such as diabetic foot ulcers and pressure sores. The company has developed proprietary expertise and a unique clinically integrated GMP operational service model to provide their proprietary RAPID™ Biodynamic Haematogel supporting clinicians with an interest in wound care to have additional treatment options. Foresight invested £3 million in BTS to support the business and accelerate growth. HMT, led by James Thomas acted as lead advisors to BTS on the transaction which included assessing the strategic options for the shareholders and management, identifying suitable investment partners, negotiating detailed investment terms and project managing the deal to a successful completion. |
| Industry Sector | Healthcare |
| ICFG Office | London |
HMT, ICFG member based in the UK, advised specialist pharmaceutical biotech company Biotherapy Services Ltd (“BTS”) on their Series A fundraising. Foresight VCT (“Foresight”) invested £3 million to support the growth of the business supplemented by further investment from existing and new private investors.
